KIAT Bio Industry Open Ecosystem Promotion — Round 2 Integrated
Funds Korean bio industrial ecosystems by supporting ecosystem development and collaboration.
⚠ This may reflect a past cycle — verify the current call on the funder's site.
The 2026 Bio Industry Open Ecosystem Promotion Program — Round 2 Integrated Call is a KIAT grant supporting the development of shared infrastructure and open-access platforms for Korea's bio industry. The program targets mid-to-late TRL projects (TRL 5–8) that build out enabling facilities — such as pilot GMP manufacturing lines, translational research platforms, and open analytical laboratories — that multiple bio-sector users can access, rather than funding the proprietary R&D of a single company. This open-ecosystem model reflects a Korean industrial policy priority to reduce duplication of expensive bio infrastructure and accelerate the translational pipeline from research discovery to clinical or commercial production. KIAT issued the Round 2 integrated call on 15 May 2026, with a submission deadline of 8 June 2026, representing a three-week window characteristic of integrated planning-type calls.
Eligible applicants include for-profit enterprises, non-profit organisations, universities, and research institutions registered in Korea. In practice, consortium structures are typical: a host organisation anchors the shared facility or platform, with downstream user-recruitment milestones committed as deliverables. Award values for this round were not published in the available records; prior rounds of related KIAT bio-infrastructure calls have ranged from several hundred million KRW to multi-billion KRW depending on infrastructure scope. This Round 2 call is distinct from the KIAT EUREKA Advanced Bio international joint R&D track, which funds cross-border R&D consortia rather than domestic shared infrastructure.
Applicants should note the short submission window and the Korean-language submission requirement via the KIAT portal. Proposals are assessed on the breadth of potential downstream user-base, the open-access governance model for the facility, and alignment with KIAT's bio-industry strategic roadmap. A subsequent round within 2026 is anticipated.
Grants for building shared open-access infrastructure — pilot GMP lines, translational platforms, and analytical facilities — serving multiple participants in Korea's bio industry.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see the timeline